MindMed Reports the Results for MM120 in P-IIb Trial and Receives US FDA’s BTD for the Treatment of Generalized Anxiety Disorder (GAD)
Shots:
- The company received the US FDA’s BTD for MM120 & highlighted the results from the P-IIb (MMED008) clinical trial evaluating the safety & efficacy of MM120 (100 µg) vs PBO in patients with GAD for a duration of 12wks.
- The results from the study depicted a 7.7-point improvement in HAM-A reductions with a 65% clinical response rate & 48% clinical remission rate & an improvement in CGI-S from 4.8 to 2.22 with MM120 vs PBO. The company expects to present these results at the APA 2024
- Additionally, the company expects to hold an End-of-Phase 2 meeting with the US FDA by H1’24 & initiate P-III evaluation of MM120 by H2’24. MM120 is a synthetic ergotamine that acts as a partial agonist at human serotonin-2A
Ref: MindMed | Image: MindMed
Related News:- MindMed Entered into an Exclusive License Agreement with Catalent for Patented Zydis Fast-Dissolve Technology Incorporated in MM-120
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
